NASDAQ:STIM Neuronetics Q3 2025 Earnings Report $3.11 +0.22 (+7.47%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Neuronetics EPS ResultsActual EPSN/AConsensus EPS -$0.11Beat/MissN/AOne Year Ago EPSN/ANeuronetics Revenue ResultsActual RevenueN/AExpected Revenue$37.85 millionBeat/MissN/AYoY Revenue GrowthN/ANeuronetics Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateTuesday, November 11, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Neuronetics Earnings HeadlinesNeuronetics management to meet virtually with Piper SandlerSeptember 23, 2025 | msn.comNeuronetics Gains Breakthrough as New York Medicaid Expands Coverage for TMS Depression TherapySeptember 20, 2025 | msn.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.October 15 at 2:00 AM | Priority Gold (Ad)Neuronetics, Inc.'s (NASDAQ:STIM) last week's 25% decline must have disappointed individual investors who have a significant stakeSeptember 17, 2025 | finance.yahoo.comNew York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)September 17, 2025 | globenewswire.comUnusually active option classes on open September 9thSeptember 9, 2025 | msn.comSee More Neuronetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuronetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuronetics and other key companies, straight to your email. Email Address About NeuroneticsNeuronetics (NASDAQ:STIM) is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation. The company’s platform is designed for use in outpatient clinics, hospitals and psychiatry practices across the United States. Neuronetics maintains a specialized field sales force and collaborates with key channel partners to support physician training, patient education and therapy delivery. In addition to its commercial activities, the company continues to explore new indications and protocol optimizations to expand its therapeutic offerings. Guided by a leadership team with deep experience in medical devices and neuroscience, Neuronetics strives to improve patient outcomes through research, regulatory engagement and post-market data collection. The company’s ongoing efforts include refining device features, enhancing treatment compliance and evaluating the use of its technology in other neuropsychiatric conditions. Neuronetics is publicly traded on the Nasdaq under the symbol STIM.View Neuronetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings Interactive Brokers Group (10/16/2025)CSX (10/16/2025)American Noble Gas (10/16/2025)U.S. Bancorp (10/16/2025)Charles Schwab (10/16/2025)Bank of New York Mellon (10/16/2025)Marsh & McLennan Companies (10/16/2025)Travelers Companies (10/16/2025)Taiwan Semiconductor Manufacturing (10/16/2025)HDFC Bank (10/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
